CCCC
C4 Therapeutics, Inc.
There isn't enough reported data to score CCCC yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CCCC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
CCCC's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CCCC PE Valuation
CCCC has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CCCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CCCC's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CCCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.63 | +$1.05 |
| Q2 2026 | -$0.91 | +$0.68 |
| Q1 2026 | -$1.10 | +$0.38 |
| Q4 2025 | -$1.27 | +$0.25 |
| Q3 2025 | -$1.68 | +$0.02 |
| Q2 2025 | -$1.59 | +$0.31 |
| Q1 2025 | -$1.48 | +$0.89 |
| Q4 2024 | -$1.52 | +$1.15 |
CCCC has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CCCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.5M | -25% |
| Q2 2026 | $6.6M | +2.8% |
| Q1 2026 | $6.2M | -15% |
| Q4 2025 | $11M | +113% |
| Q3 2025 | $11.2M | -27% |
| Q2 2025 | $6.5M | -46% |
| Q1 2025 | $7.2M | +138% |
| Q4 2024 | $5.2M | +59% |
CCCC's revenue is growing: $8M last quarter, down 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -290% | +16 points |
| Q2 2026 | -398% | +43 points |
| Q1 2026 | -452% | -49 points |
| Q4 2025 | -210% | +518 points |
| Q3 2025 | -306% | -123 points |
| Q2 2025 | -441% | -262 points |
| Q1 2025 | -403% | +657 points |
| Q4 2024 | -728% | +419 points |
CCCC's operating margin was −290% last quarter, up 16 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CCCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CCCC on profitability, with a higher operating margin.
CCCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26M | +$5.7M |
| Q1 2026 | -$30M | +$3.3M |
| Q4 2025 | -$22.2M | -$4.2M |
| Q1 2025 | -$33.3M | -$15.2M |
| Q4 2024 | -$17.9M | +$6.2M |
| Q1 2024 | -$18.1M | +$15.6M |
| Q4 2023 | -$24.2M | +$6.5M |
| Q1 2023 | -$33.7M | -$6.9M |
CCCC has burned cash in almost every quarter: −$80M over the past year, against −$101M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CCCC on cash generation, producing positive trailing cash flow while its opponent burns cash.
CCCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +5.4M shares |
| 1 year | +88% | +63.5M shares |
| 3 years | +177% | +87M shares |
| 5 years | +210% | +92.2M shares |
| Available history | +690% | +119M shares |
CCCC has 136M diluted shares, up 88% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $39,000 |
| Q2 2026 | — |
| Q1 2026 | $200,000 |
| Q4 2025 | $14,000 |
| Q3 2025 | $24,000 |
| Q2 2025 | — |
| Q1 2025 | $155,000 |
| Q4 2024 | — |
CCCC has spent almost nothing on buybacks in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CCCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CCCC Net Leverage
CCCC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CCCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 27.4 | Neutral |
CCCC's weekly RSI is 42 (neutral) and its Stochastic is 27 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CCCC PE vs Healthcare Sector
CCCC has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CCCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.02 | 8.3% below |
| 20 week MA | $3.48 | 20% below |
| 50 week MA | $3.07 | 9.8% below |
| 100 week MA | $2.72 | 1.8% above |
| 200 week MA | $3.77 | 27% below |
CCCC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CCCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $35.4 | +39% |
| 2021 | $35.4 | $33.4 | -5.8% |
| 2022 | $33.4 | $6.08 | -82% |
| 2023 | $6.08 | $5.65 | -7.1% |
| 2024 | $5.65 | $3.79 | -33% |
| 2025 | $3.79 | $2.12 | -44% |
| 2026 YTD | $2.12 | $2.77 | +31% |
CCCC has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.